Skip to main content
OpenTrials
Enrolling by Invitation

NCT Number: NCT07572227

Fetal Cystoscopy in the Management of Lower Urinary Tract Obstruction (LUTO)

The purpose of this research is to determine the feasibility and safety of performing fetal operative cystoscopy for the treatment of Lower Urinary Tract Obstruction (LUTO) using investigational devices.

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Mayo Clinic

Rochester, Minnesota, 55905, United States

About this study

Fetal cystoscopy involves the use of a tiny camera to find the cause of the urinary tract blockage and to treat it at the same time. When a fetus is found to have LUTO, this means there is a blockage in the urethra (tube that passes urine from the bladder to outside the body) which leads to kidney, lung, and other organ damage in the fetus.

Fetal surgery is when the unborn baby is in the mother's uterus (in utero). This study will see if certain investigational devices are safe for the fetal cystoscopy procedure.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18 years of age or older
  • Pregnant women carrying a singleton gestation and male fetus
  • Able to perform the procedure at a gestational age between 16 0/7 and 25 6/7 weeks of gestation
  • Lower urinary tract obstruction: Enlarged bladder (subjectively assessed), keyhole sign, bladder wall thickening (subjectively assessed), and bilateral hydro (uretero) nephrosis.27
  • Absence of chromosomal abnormalities and other anomalies unrelated to the urinary tract obstruction.
  • Oligo or anhydramnios at or after 16 weeks of gestation
  • Evidence of conserved renal function (a Nassr et al., score of 3 or less ).
  • Able to understand the requirements of the study, and willing and able to consent for enrollment in the study

Exclusion criteria

  • Severe maternal health condition precluding procedure.
  • Increased risk for preterm labor including short cervical length, history of incompetent cervix with or without cerclage, and previous preterm birth
  • Placental abnormalities (previa, abruption, accreta) known at time of enrollment
  • Contraindications to surgery including previous hysterotomy in active uterine segment (at or above the level of the round ligaments).
  • Maternal-fetal Rh isoimmunization, Kell sensitization or neonatal alloimmune thrombocytopenia affecting the current pregnancy
  • Maternal HIV, Hepatitis-B, Hepatitis-C status positive because of the increased risk of transmission to the fetus during maternal-fetal surgery o
  • Female fetus
  • Significant pathogenic or likely pathogenic finding on karyotype or microarray
  • Significant unrelated fetal anomaly, as opposed to a nonsignificant one that would not preclude enrollment.
  • Multiple gestation
  • Technical limitations precluding the procedure, such as, no fetoscopic approach due to placental position or fetal position.
  • Inability to comply with travel and follow-up requirements of the trial

Treatment and study plan

Fetal cystoscope

Device

The fetoscope assembly includes the the Boston Scientific Maverick 2 balloon catheter and Emerge balloon, the Karl Storz Miniature Straight Forward Telescope, Operating Sheath, and connector.

A fetal cystoscopy will be performed for treatment of lower urinary tract obstruction complicated by oligo/anhydramnios.

Primary outcomes

  1. Number of procedures that achieved technical success of visualization of the bladder neck and proximal urethra

    Time frame: 24 months

    Technical success of visualization is defined as the ability to visualize the bladder neck and proximal urethra during the procedures.

  2. Number of procedures that achieved technical success of posterior urethral valve ablation with laser to allow passage of balloon

    Time frame: 24 months

    Technical success of posterior urethral valve ablation with laser to allow passage of balloon is defined as completing urethral valve ablation during the procedure.

  3. Number of procedures that achieved technical success of valvuloplasty

    Time frame: 24 months

    Technical success of valvuloplasty is defined as passage of balloon during dilation of valve.

Secondary outcomes

  1. Amniotic fluid volume after the procedure (major vertical pocket)

    Time frame: 24 hours after procedure

    Amniotic fluid volume is reported based on ultrasound measurements of Maximum Vertical Pocket (MVP), and is reported in centimeters (cm)

  2. Fetal lung growth after treatment

    Time frame: Baseline

    Fetal lung growth will be determined by observed Lung area to Head circumference Ratio (LHR) = Lung area / Head circumference

  3. Number of fetuses to experience complications

    Time frame: Baseline

    Fetal safety will be assessed as number of fetuses to experience complications, defined as premature delivery, prelabor rupture of membranes, injury to the fetus, abdominal hernia, vesicoamniotic or vesicoperitoneal fistula, chorioamniotic separation, fetal bleeding, bradycardia, fetal anemia, brain injury, or death

  4. Number of mothers to experience complications

    Time frame: Baseline

    Maternal safety will be assessed as number of mothers to experience complications, defined as wound infection, chorioamnionitis, bleeding, injury to surrounding organs, amniotic fluid leak, prelabor rupture of membranes, placental abruption, preterm delivery, pseudomembranous colitis, mirror syndrome/preeclampsia, or death.

  5. Gestational age at delivery

    Time frame: Gestational age at delivery, up to 9 months

    Gestational age at time of delivery, reported in weeks

  6. Renal changes after treatment

    Time frame: 24 months

    Number of patients to experience renal pelvis anteroposterior diameter, presence or absence of renal cystic changes, improvement or worsening of hydronephrosis

  7. Survival rate

    Time frame: 28 days, 3 months, 6 months, 12 months, 18 months, and 24 months of age

    Survival of neonates at post natal follow up points of 28 days, 3 months, 6 months, 12 months, 18 months, and 24 months of age

  8. Serum creatinine level

    Time frame: 28 days, 3 months, 6 months, 12 months, 18 months, and 24 months of age

    Serum creatinine level will be measured by blood test

  9. Need for dialysis

    Time frame: 28 days, 3 months, 6 months, 12 months, 18 months, and 24 months of age

    Number of neonates to require dialysis

  10. Grading of oxygen dependency

    Time frame: 28 days, 3 months, 6 months, 12 months, 18 months, and 24 months of age

    Grading of oxygen dependency is categorized as: none, mild, moderate, or severe

  11. Occurrence of severe pulmonary hypertension

    Time frame: Baseline

    Number of neonates to show indications of severe pulmonary hypertension based on latest echocardiogram during first hospitalization.

  12. Use of extracorporeal membrane oxygenation (ECMO) support during post-natal follow-up

    Time frame: 24 months

    Number of neonates to require ECMO support at any point during the first 24 months

  13. Days in neonatal intensive care unit during the first hospitalization

    Time frame: During first hospitalization (assessed up to 10 days)

    Total number of days in neonatal intensive care unit during the first hospitalization

  14. Ventilator support during the first hospitalization

    Time frame: During first hospitalization (assessed up to 10 days)

    Total number of days of ventilator support during the first hospitalization

  15. Presence of neonatal sepsis

    Time frame: Baseline

    Total number of neonates to experience neonatal sepsis, defined as intraventricular hemorrhage (grade 3 or higher), retinopathy of prematurity (grade 3 or higher).

  16. Total number of patients to require surgery

    Time frame: Baseline

    Total number of patients to require surgery to treat posterior urethral valves or to deal with complications of in utero procedure

  17. Days of maternal hospitalization.

    Time frame: Two weeks from day of admission

    Total number of days in hospital after giving birth

  18. Operative times

    Time frame: During procedure

    Length of time to complete fetal cystoscopy, reported in minutes

Sponsors and collaborators

Lead sponsor

Mayo Clinic

Other

Registry information

Important dates

Study start
2026
Primary completion
2056
Study completion
2060
First posted
May 7, 2026
Registry last updated
Jul 24, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.